# EDGAR Filing Document

**Accession Number:** 0001286199
**File Stem:** 0000950170-25-081939
**Filing Date:** 2025-6
**Character Count:** 9743
**Document Hash:** 931c2a48c9eac5dfc35cbb1a8fdf283d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-081939.hdr.sgml**: 20250604

**ACCESSION NUMBER**: 0000950170-25-081939

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250602

**FILED AS OF DATE**: 20250604

**DATE AS OF CHANGE**: 20250604

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** BELANOFF JOSEPH K
- **CENTRAL INDEX KEY:** 0001286199

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-50679
- **FILM NUMBER:** 251024806

**MAIL ADDRESS:**
- **STREET 1:** 149 COMMONWEALTH DRIVE
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CORCEPT THERAPEUTICS INC
- **CENTRAL INDEX KEY:** 0001088856
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 770487658
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 101 REDWOOD SHORES PARKWAY
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** 650.688.8803

**MAIL ADDRESS:**
- **STREET 1:** 101 REDWOOD SHORES PARKWAY
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>BELANOFF JOSEPH K<br><sub>(Last) (First) (Middle)</sub><br>C/O CORCEPT THERAPEUTICS INCORPORATED<br>101 REDWOOD SHORES PARKWAY<br><sub>(Street)</sub><br>REDWOOD CITY, CA 94065<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>CORCEPT THERAPEUTICS INC [ CORT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-06-02 |  | S<sup>(1)</sup> |  | 4881 | D | 78.4211<sup>(2)</sup> | 2937104 | I | Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02<sup>(3)</sup> |
| Common Stock | 2025-06-02 |  | S<sup>(1)</sup> |  | 3050 | D | 79.4823<sup>(4)</sup> | 2934054 | I | Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02<sup>(3)</sup> |
| Common Stock | 2025-06-02 |  | S<sup>(1)</sup> |  | 2988 | D | 80.3017<sup>(5)</sup> | 2931066 | I | Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02<sup>(3)</sup> |
| Common Stock | 2025-06-02 |  | S<sup>(1)</sup> |  | 1820 | D | 81.3255<sup>(6)</sup> | 2929246 | I | Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02<sup>(3)</sup> |
| Common Stock | 2025-06-02 |  | S<sup>(1)</sup> |  | 1263 | D | 82.2634<sup>(7)</sup> | 2927983 | I | Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02<sup>(3)</sup> |
| Common Stock | 2025-06-02 |  | S<sup>(1)</sup> |  | 4631 | D | 83.4643<sup>(8)</sup> | 2923352 | I | Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02<sup>(3)</sup> |
| Common Stock | 2025-06-02 |  | S<sup>(1)</sup> |  | 12959 | D | 84.5715<sup>(9)</sup> | 2910393 | I | Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02<sup>(3)</sup> |
| Common Stock | 2025-06-02 |  | S<sup>(1)</sup> |  | 8408 | D | 85.0116<sup>(10)</sup> | 2901985 | I | Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02<sup>(3)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

(2) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $77.84 to $78.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

(3) Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

(4) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $78.88 to $79.865 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

(5) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.90 to $80.8925 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

(6) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.92 to $81.78 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

(7) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.935 to $82.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

(8) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.96 to $83.95 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

(9) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.975 to $84.94 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

(10) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.00 to $85.31 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

**Remarks:**
The power of attorney under which this form was signed is on file with the Commission.

**Signature:** /s/ Joseph Douglas Lyon, as attorney-in-fact for Joseph K. Belanoff.  
**Date:** 2025-06-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**